← Back to Search
Envisioning Future Strategies For Vaccination Against Tuberculosis
Published 2006 · Medicine
Download PDFAnalyze on Scholarcy
The design of tuberculosis vaccines has entered a new era. Although several new vaccine candidates will pass Phase I clinical trials within the next year, I believe that the most effective vaccination strategy will be to combine different vaccine candidates and to use a prime–boost approach. This strategy, however, would require several years of iterative vaccine trials, unless the process is expedited by the identification of reliable biomarkers for assessing vaccine efficacy. In this Essay, I briefly summarize past and present attempts to develop a vaccine against tuberculosis, and I describe, using imagined scenarios, the tuberculosis vaccination schemes that might become available from a large repertoire of candidate schemes in the near and distant future.
This paper references
Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin.
L. Grode (2005)
Sur la vaccination préventive des enfants nouveau-nés contre la tuberculose par le BCG
A. Calmette (1927)
Differential Immune Responses and Protective Efficacy Induced by Components of a Tuberculosis Polyprotein Vaccine, Mtb72F, Delivered as Naked DNA or Recombinant Protein1
Y. Skeiky (2004)
CORRIGENDUM: Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis
E. StefanH.E.KaufmannSH (2005)
Protective Effect of a Tuberculosis Subunit Vaccine Based on a Fusion of Antigen 85B and ESAT-6 in the Aerosol Guinea Pig Model
A. Olsen (2004)
New insights into the function of granulomas in human tuberculosis
T. Ulrichs (2006)
Protein Kinase G from Pathogenic Mycobacteria Promotes Survival Within Macrophages
Anne Walburger (2004)
Die Säuglingstuberkulose in Lübeck (Springer, Berlin, 1935) (in German)
H. Reiter (1935)
La vaccination preventive contre la tuberculose par le "BCG"
A. Calmette (1927)
Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.
M. Horwitz (2000)
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans
H. McShane (2004)
Recent findings in immunology give tuberculosis vaccines a new boost.
S. Kaufmann (2005)
Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis
S. Kaufmann (2005)
Verhandlungen des X. Internationalen Medicinischen Congresses : Berlin, 4.-9. August 1890
This paper is referenced by
Immune intervention strategies against tuberculosis
S. Kaufmann (2011)
How do adjuvants work? Important considerations for new generation adjuvants.
Amy S McKee (2007)
Evaluation of immunogenicity and protective efficacy against Mycobacterium tuberculosis infection elicited by recombinant Mycobacterium bovis BCG expressing human Interleukin‐12p70 and Early Secretory Antigen Target‐6 fusion protein
Y. Deng (2011)
Learning from natural infection for rational tuberculosis vaccine design:From basic science to translational research
S. Kaufmann (2010)
Novel vaccination strategies against tuberculosis.
P. Andersen (2014)
L’apport des nouvelles technologies en vaccinologie
C. Leclerc (2007)
Immune evasion and identification of biomarkers associated with mycobacterial infection
J. Arko-Mensah (2007)
A novel recombinant BCG-expressing pro-apoptotic protein BAX enhances Th1 protective immune responses in mice.
G. Li (2015)
Exploring functional genomics for the development of novel intervention strategies against tuberculosis.
H. Rachman (2007)
The secretome of a recombinant BCG substrain reveals differences in hypothetical proteins.
Mauricio Rodríguez-Álvarez (2010)
Assessment of the Immune Response Induced in Neonatal Calves By Vaccination With Mycobacterium Bovis BCG Phipps Under Field Conditions
Eve-Lyne Quevillon (2017)
Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials
J. G. Asensio (2008)
Mycobacterium tuberculosis H37Rv: In Silico Drug Targets Identification by Metabolic Pathways Analysis
Asad Amir (2014)
Tuberculosis in Africa: learning from pathogenesis for biomarker identification.
S. Kaufmann (2008)
Low dose BCG vaccination in mice : immune responses and implications for tuberculosis control
Tadele Kiros Gebreyohannes (2007)
Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen.
Y. Skeiky (2010)
Antigen-presenting cells transfected with Hsp65 messenger RNA fail to treat experimental tuberculosis
C. Rocha (2012)
Early T‐cell responses in tuberculosis immunity
G. Winslow (2008)
Drug targets identification of Mycobacterium tuberculosis by metabolic pathway analysis: insilico process
A. Ghosh (2017)
Expression and regulation of chemokines in mycobacterial infection.
P. Méndez-Samperio (2008)
The role of dendritic cells in Mycobacterium tuberculosis infection
A. Mihret (2012)
The recombinant tuberculosis vaccine rBCG ΔureC::hly(+) induces apoptotic vesicles for improved priming of CD4(+) and CD8(+) T cells.
Maura Farinacci (2012)
Secreted transcription factor controls Mycobacterium tuberculosis virulence
S. Raghavan (2008)
Heterologous prime–boost vaccinations for poverty-related diseases: advantages and future prospects
K. Radošević (2009)
Identification of a Glucose Permease from Mycobacterium smegmatis mc2 155
Elisângela F. Pimentel-Schmitt (2008)
New vaccines for tuberculosis
S. Kaufmann (2010)
Global control of infectious diseases by vaccination programs
R. Tangermann (2007)
Influence of BCG dose and age of inoculated mice on immunoprotection against tuberculosis and expression of IFN-γ/IL-4
Guo Hui-jun (2009)
Multi-Drug/Extensively Drug Resistant Tuberculosis (Mdr/Xdr-Tb): Renewed Global Battle Against Tuberculosis?
C. Kirimuhuzya (2012)
Novel particulate BCG-loaded delivery system for mucosal immunization against tuberculosis
L. A. Caetano (2016)
Mycobacterium tuberculosis nuoG Is a Virulence Gene That Inhibits Apoptosis of Infected Host Cells
K. Velmurugan (2007)
T cell plasticity and co-infections in mycobacterial diseases.
Leticia Monin Aldama (2015)See more